LINC00893 is downregulated and miR-103a-3p upregulated in T2DM with CHD; low LINC00893 predicts higher MACE risk and regulates miR-103a-3p.
Are LINC00893 and miR-103a-3p expression levels altered in T2DM patients with CHD, and do they have diagnostic and prognostic significance?
LINC00893 and miR-103a-3p may serve as diagnostic and prognostic biomarkers for coronary heart disease and MACE in patients with type 2 diabetes.
Absolute Event Rate: 0% vs 0%
Background Coronary heart disease (CHD) is a prevalent complication associated with type 2 diabetes mellitus (T2DM), and the incidence of T2DM with CHD has seen a steady rise over the preceding years. Objective To investigate the altered expression of LINC00893 and miR-103a-3p in T2DM and T2DM with CHD, as well as to assess their clinical significance in T2DM-CHD. Methods The LINC00893 and miR-103a-3p expression was detected by RT-qPCR. ROC curves were used to analyze the diagnostic significance of LINC00893 and miR-103a-3p in T2DM patients with CHD. The Kaplan-Meier curve was used to analyze the prognostic significance of LINC00893 in the occurrence of Major Adverse Cardiovascular Events (MACEs) of T2DM with CHD patients. Dual-luciferase reporter assay was used to confirm the regulatory relationship between LINC00893 and miR-103a-3p. Result LINC00893 and miR-103a-3p were down-regulated and up-regulated in T2DM with CHD patients, respectively and had diagnostic value in T2DM with CHD patients. In addition, patients with low levels of LINC00893 are more likely to develop MACE, and LINC00893 could regulate the expression of miR-103a-3p. Conclusion LINC00893 may affect disease progression in T2DM patients with CHD by regulating miR-103a-3p.
Fang et al. (Thu,) reported a other. LINC00893 is downregulated and miR-103a-3p upregulated in T2DM with CHD; low LINC00893 predicts higher MACE risk and regulates miR-103a-3p.